

# Anti-CD20 (Rituximab), Chimeric Antibody

Catalog # ABV11759

## Product Information

---

|                   |                           |
|-------------------|---------------------------|
| Application       | E                         |
| Primary Accession | <a href="#">NP_690605</a> |
| Reactivity        | Human                     |
| Host              | Human/Mouse Chimeric      |
| Clonality         | Monoclonal                |
| Isotype           | Human IgG1                |

## Additional Information

---

|                          |                                                                                                                            |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Application & Usage      | Activation : 1-20 $\mu$ g/ml; ELISA: 2 $\mu$ g/ml                                                                          |
| Alias Symbol             | CD20                                                                                                                       |
| Other Names              | MabThra                                                                                                                    |
| Appearance               | Colourless liquid                                                                                                          |
| Formulation              | 100 ug (2mg/ml) of antibody in Phosphate buffered saline, pH 7.4.                                                          |
| Reconstitution & Storage | -20 °C                                                                                                                     |
| Background Descriptions  |                                                                                                                            |
| Precautions              | Anti-CD20 (Rituximab), Chimeric Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |

## Protein Information

---

### Background

---

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and antibody dependent cellular cytotoxicity. Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.